The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs -- Combat Readiness – Medical Research Program -- Rapid Development and Translational Research Award
Proposals/applications to the FY21 CRRP RDTRA are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by 10 USC 2358. The U.S. Army Medical Research and Development Command (USAMRDC) Congressionally Directed Medical Research Programs (CDMRP) is the execution management agent for this BAA.
The CRRP was initiated by Congress in FY19 with an appropriation of $15 million (M) to pursue military-relevant advanced technology and therapeutic research. Specifically, the CRRP focuses on forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Warfighters in current and future battlefield settings. Appropriations for the CRRP from FY19 through FY20 totaled $25M. The FY21 appropriation is $10M.
The CRRP vision is to deliver high-impact medical solutions in diverse operational settings and closer to the point of injury to increase survivability and Warfighter readiness. The program seeks to develop innovative solutions to increase medical readiness, mitigate fatalities, optimally treat life-threatening injuries, and promote positive long-term outcomes. While the CRRP focuses on capability gaps in frontline care, the program also considers how chronic disorders typically associated with pre-deployment readiness (e.g., sleep, gastrointestinal conditions, posttraumatic arthritis) may influence the delivery of care in deployed environments and contribute to injury susceptibility and recovery. Innovations developed by CRRP-supported research may be applied proactively as a way to establish medical readiness ahead of deployment, in operational settings at the point of injury, during periods of prolonged care, or during transport/en route between roles of care. These solutions will not only help to minimize the morbidity and mortality of combat-related injuries sustained by the Warfighter, they will also often translate to civilian care.
The CRRP seeks to enhance medical capabilities and Force readiness at the point of greatest need in order to save the most lives in trauma care scenarios, which may be complicated by combat operations, limited resources, austere conditions, and/or mass casualty events. The intent of the FY21 CRRP RDTRA is to support research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines. Research under this award mechanism should represent a rapid advancement or innovative “leap ahead” and have the potential for broadly applicable, crosscutting advances benefiting military health and medicine as well as the general public. Applicants may leverage existing resources in translational research to address high-impact research ideas or unmet needs to enable the delivery of life-saving care to the Warfighter during prolonged and en route care in austere and combat environments.
• Required Pre-Application Deadline: Aug. 31, 2021
• Application Submission Deadline: December 1, 2021
Areas of Interest
The Focus Areas were established from research priorities described in the Congressional Committee Report for the CRRP in FY21. These Focus Areas broadly describe current priorities to improve readiness for delivering frontline care in combat situations and for delivering medical damage control capability, assets, and life-saving interventions during prolonged and en route care in austere and combat environments, including the acute and early management of combatrelated trauma at the point of injury. Proposals/applications submitted to the FY21 CRRP RDTRA must address at least one of the FY21 CRRP Focus Areas listed below. Selection of the appropriate FY21 CRRP Focus Area is the responsibility of the applicant.
Funding should be used for the research and development of one of the following Focus Areas:
- Solutions to enhance Warfighter readiness, such as solutions to address: ○ Infectious diseases ○ Sleep disorders ○ Myalgic encephalomyelitis/chronic fatigue syndrome ○ Service-related post-traumatic arthritis
- Solutions to enhance combat care delivery throughout the far-forward environment, such as: ○ Telemedicine solutions that enable medical capabilities at far-forward battlespace locations worldwide ○ Medical simulation technology that supports sustainment of critical skills and medical decision-making ○ Freeze-dried plasma and platelets ○ Ruggedized oxygen generation systems ○ Solutions for the assessment of mild traumatic brain injury, to include portable devices
- Wound care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care (e.g., acute through chronic care), such as: ○ Multi-modal wound care solutions that provide a combination of hemostasis, wound healing, infection prevention, and/or analgesia ○ Traumatic wound care to prevent sepsis ○ Repair and restoration of genitourinary injury and tissue damage
Independent investigators at all academic levels (or equivalent) are eligible to be named by the organization as the PI in the proposal/application. There are no limitations on the number of proposals/applications for which an investigator may be named as a PI. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
RDTRA: The period of performance of the RDTRA will be 2 years. The anticipated total costs budgeted for an FY21 CRRP RDTRA will not exceed $1.8M.
RDTRA with Option (if applicable): The RDTRA with Option may be funded in two phases over a 3-year period. The initial period of performance of the RDTRA will be 2 years. The period of performance of the Option will be 1 year. Each phase must be a distinct, but related, research effort with a non-overlapping period of performance, research outcomes/milestones, and budget. The Option must clearly be a follow-on effort stemming from the work completed during the base RDTRA. Research products from the RDTRA shall be leveraged in the subsequent option phase, if planned. The anticipated total costs budgeted will not exceed $1.8M for an FY21 CRRP RDTRA and $1.0M for the Option period of performance.